Cetyl Myristoleate
CMO for joint lubrication, arthritis relief, and immune modulation
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Always consult your physician before starting any supplement.
Cetyl Myristoleate (CMO) is a fatty acid ester — specifically the cetyl ester of myristoleic acid — first identified in the 1960s by USDA researcher Harry Diehl. The discovery came from investigating why Swiss albino mice appeared naturally resistant to adjuvant-induced arthritis. The compound responsible turned out to be CMO, found in small amounts in their tissues. This observation sparked decades of research into CMO as a therapeutic agent for human joint conditions.
CMO is present in tiny quantities in some animal tissues and certain plant oils but at concentrations far too low to be therapeutically relevant from food alone. As a supplement, it is typically derived from beef tallow or synthesized, and often sold as a blend of cetylated fatty acids (cetyl myristoleate, cetyl myristate, cetyl palmitate, and others). The proposed mechanisms include acting as a joint lubricant within synovial membranes, modulating immune responses by influencing prostaglandin and leukotriene production (similar to essential fatty acids), and potentially supporting myelin sheath integrity. The clinical evidence, while not as extensive as for Boswellia or MSM, is genuinely positive — and in a supplement store context, CMO was consistently one of the products that generated the most loyal repeat customers among people with joint issues who had not responded fully to other options.
Knee Osteoarthritis Relief
The most rigorous clinical trial to date (Kraemer et al., 2004) found that a cetylated fatty acid blend significantly improved knee function, range of motion, and pain scores in knee OA patients compared to placebo after 30 days. Improvements in muscle function and stair-climbing ability were statistically significant, suggesting functional joint benefit beyond simple pain relief.
Range of Motion
Both oral and topical CMO formulations have been associated with improved joint range of motion in OA trials. The lubrication mechanism — if valid — would explain this particular effect, as stiff joints often benefit more from lubrication than from pure anti-inflammatory approaches. CMO is one of the few joint supplements where range-of-motion improvement has been specifically measured and reported.
Anti-Inflammatory Modulation
Cetylated fatty acids may reduce the production of pro-inflammatory prostaglandins by competing with arachidonic acid in cell membranes, similar to how omega-3 fatty acids work. This immune-modulating effect is the favored mechanistic explanation among researchers for why CMO helps not just in OA but in some autoimmune-related joint conditions as well.
Non-Responder Option
In practice, CMO tends to work well for people who have tried glucosamine, chondroitin, and even Boswellia without adequate relief. Its distinct mechanism makes it a rational next step or complementary addition rather than a substitute. Several practitioners use it specifically for patients who have not responded to first-line joint supplements.
CMO has a smaller clinical trial base than Boswellia or MSM. The most cited positive RCT (Kraemer 2004) is well-designed but used a combination of cetylated fatty acids, not pure CMO alone. The original Diehl registry study was observational. More independent RCTs are needed. That said, the available evidence is positive, safety is excellent, and the mechanism is plausible. We consider it worth trying — especially for those who haven’t achieved full relief from other joint supplements.
- Take with food — as a fatty acid ester, CMO absorbs better in the presence of dietary fat
- Allow at least 30 days before evaluating; some users see results within 2 weeks, others take longer
- Works well alongside MSM and Boswellia — complementary mechanisms, not redundant
- Excellent safety profile — no known serious adverse effects at recommended doses
A 2004 double-blind RCT by Kraemer et al. published in the Journal of Rheumatology enrolled 40 subjects with knee osteoarthritis and assigned them to a cetylated fatty acid complex or placebo for 30 days. The CMO group showed statistically significant improvements in knee flexion range of motion (+10.1° vs. +3.5°), stair-climbing performance, and overall physical function scores. The study also measured muscle strength and found meaningful improvements in the treated group. This remains the most rigorous RCT for CMO and demonstrates a functional benefit — not just pain reduction — within 30 days.
How Cetyl Myristoleate Compares
| Ingredient | Best For | Key Difference |
|---|---|---|
| Cetyl Myristoleate | Joint lubrication, range of motion, non-responders | Fatty acid ester; lubrication + immune modulation mechanism |
| Boswellia | Joint pain, arthritis, anti-inflammatory | 5-LOX inhibition; stronger anti-inflammatory evidence base |
| MSM | Joint pain, connective tissue, exercise recovery | Sulfur supply + NF-κB inhibition; structural and anti-inflammatory |
| Glucosamine | Cartilage maintenance, long-term OA management | Structural building block; slower, more preventive than CMO |
CMO is best viewed as a complementary or second-line option within a comprehensive joint health stack.
- Kraemer WJ, et al. Effect of a cetylated fatty acid topical cream with menthol on functional mobility and quality of life of patients with either chronic knee pain or self-assessed arthritic knee pain. J Rheumatol. 2004;31(4):767–774.
- Hesslink R Jr, et al. Cetylated fatty acids improve knee function in patients with osteoarthritis. J Rheumatol. 2002;29(8):1708–1712.
- Diehl HW, May EL. Cetyl myristoleate isolated from Swiss albino mice: an apparent protective agent against adjuvant arthritis in rats. J Pharm Sci. 1994;83(3):296–299.
Evidence-based supplement recommendations from a former physical store owner. No hype. No BS. Just facts.
Download Free PDF